We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Mirum Pharmaceuticals Inc (MIRM) USD0.0001

Sell:$21.74 Buy:$21.76 Change: $1.80 (9.01%)
Market closed |  Prices as at close on 5 July 2022 | Switch to live prices |
Change: $1.80 (9.01%)
Market closed |  Prices as at close on 5 July 2022 | Switch to live prices |
Change: $1.80 (9.01%)
Market closed |  Prices as at close on 5 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of therapies for rare and orphan diseases. The Company's main focus is the development and commercialization of LIVMARLI (maralixibat) oral solution (Livmarli) and Volixibat. Its pipeline consists of rare pediatric indications for Livmarli and orphan adult indications for its second product candidate, Volixibat. Livmarli is an oral solution as a once-daily medicine for cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. Volixibat, is an oral, minimally absorbed agent designed to inhibit ileal bile acid transporter (IBAT), for the treatment of adult patients with cholestatic liver diseases. The Company is developing volixibat for the treatment of intrahepatic cholestasis of pregnancy (ICP), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC).

Contact details

950 Tower Ln Ste 1050
United States
+1 (650) 6674085

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$636.07 million
Shares in issue:
31.84 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Michael Grey
    Chairman of the Board
  • Christopher Peetz
    President, Chief Executive Officer, Co-Founder, Director
  • Ian Clements
    Chief Financial Officer
  • Peter Radovich
    Chief Operating Officer
  • Lara Longpre
    Chief Development Officer
  • Edwin Tucker
    Chief Medical Officer
  • Pamela Vig
    Head of Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.